SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
MWN-AI** Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, is set to deliver five presentations related to its lead asset, SAB-142, at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place in Vienna, Austria, from September 15 to 19, 2025. The company focuses on developing innovative immunotherapy treatments for autoimmune type 1 diabetes (T1D), utilizing a novel platform that produces multi-specific, high-potency human immunoglobulins without relying on human donors or convalescent plasma.
Among the presentations, a notable highlight is an INNODIA-hosted symposium titled "Life-Changing T1D Therapies Symposium," featuring Dr. Alexandra Kropotova, the company’s Chief Medical Officer. The symposium aims to shed light on disease-modifying therapies that have the potential to transform the lives of those affected by T1D. In addition to the symposium, SAB BIO will have four oral presentations detailing various aspects of SAB-142's development and potential.
Key presentations include explorations into the mechanism of action of SAB-142, advancements in pharmacokinetic assays to measure its efficacy, and analyses comparing novel blood preservation techniques for multicenter clinical trials. Each presentation will feature insights from prominent SAB BIO executives, including Dr. Christoph Bausch and Dr. Eric Sandhurst.
The EASD Annual Meeting is recognized as one of the largest diabetes conferences globally, showcasing cutting-edge research in the field. SAB BIO's attendance not only highlights their commitment to addressing the significant unmet needs in T1D treatment but also emphasizes their strategic focus on advancing therapeutic options that may reshape the management of this complex autoimmune disorder.
MWN-AI** Analysis
SAB Biotherapeutics, Inc. (Nasdaq: SABS) stands at a significant inflection point as it prepares to deliver five presentations on its flagship product, SAB-142, at the upcoming 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in September 2025. The focus on type 1 diabetes (T1D), an area increasingly gaining attention for its unmet medical needs, positions the company strategically within a rapidly evolving market.
SAB-142 represents a transformative immunotherapy approach for T1D, aiming to delay or prevent disease progression through its novel mechanism of action targeting autoimmune responses. The presentations at EASD will not only provide insights into the clinical efficacy of SAB-142 but also illustrate the scientific rigor behind its development, including innovative pharmacokinetic assays and disease-modifying capabilities.
Investors should closely watch the reception of these presentations, as the outcomes could significantly influence market sentiment and ultimately stock performance. A positive reception may bolster investor confidence in SAB BIO’s potential for market penetration. Conversely, any indication of limitations in clinical effectiveness or safety could lead to volatility in the stock price.
Currently, the biopharmaceutical sector, particularly companies focused on autoimmune diseases, is witnessing robust interest resulting from advancements in precision medicine and biologic therapies. With SAB BIO’s unique production capabilities via its Transchromosomic (Tc) Bovine™ system, the company could become a strong contender in the T1D market if SAB-142 demonstrates success in upcoming trials.
In summary, while the underlying science appears promising, potential investors should stay attuned to the details revealed at the EASD meeting, considering the implications on the stock’s valuation and overall market position. Diversifying risk through gradual accumulation of shares and monitoring clinical developments will be prudent as SAB BIO navigates this critical phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61 st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 19, 2025 at the VIECON - Vienna Congress & Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.
Information on all presentations is below:
INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium
Working to Change the Lives of People Impacted ? by Type 1 Diabetes Through Unique Disease-Modifying Therapy
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Monday, September 15, 2025 | 16:40 – 20:00 CEST
Location: Lima Hall
EASD Presentations:
Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Behind the Screens: Adventures in T1D Clinical Trials | Presentation 19
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Tuesday, September 16, 2025 | 10:00 – 11:30 CEST
Location: Mumbai Hall
Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: OP 28 “Guardians of the Islet Galaxy: Protect and Replace” | Presentation 163
Presenter: Christoph Bausch, PhD, EVP and Chief Operating Officer
Presentation Date & Time: Thursday, September 18, 2025 | 10:45 – 12:15 CEST
Location: Sofia Hall
Novel Pharmacokinetic Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 391
Presenter: Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C
Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMC
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 392
Presenter: Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C
About EASD Annual Meeting
The EASD Annual Meeting is the largest diabetes conference in the world, attracting thousands of delegates. The program showcases the latest results from basic and clinical research.
For more information, visit https://www.easd.org/annual-meeting/easd-2025/ .
About INNODIA
INNODIA is an international non-profit organization that stemmed from a European-based public-private partnership co-funded by the European Commission’s Innovative Medicines Initiative (IMI-JU Joint Undertaking), The Hemsley Charitable Trust, Breakthrough T1D, and EFPIA partners. Thanks to this unique private-public interaction, INNODIA has become the largest European Network dedicated to prevent and cure type 1 diabetes and today it is a legal entity that represents the interface between those who want to develop new therapies and those who have the tools and experience to do so.
For more information, visit https://www.innodia.eu/ .
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.
CONTACTS
Investor Relations :
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Inquiries :
SAB BIO
Sheila Carlson
scarlson@sab.bio
FAQ**
What are the potential impacts of the presentations by SAB Biotherapeutics Inc. at the EASD Annual Meeting on investor sentiment towards the company's stock and the SAB Biotherapeutics Inc. Warrant SABSW?
How does the mechanism of action of SAB-142 highlight its innovative approach to treating Type 1 Diabetes compared to existing therapies, and what might this mean for the valuation of SAB Biotherapeutics Inc. Warrant SABSW?
Considering the focus on early-stage clinical trials, how might the outcomes of the presentations influence investor confidence in SAB Biotherapeutics Inc. and its related warrants, specifically SAB Biotherapeutics Inc. Warrant SABSW?
What are the expected milestones for SAB Biotherapeutics Inc. following the EASD presentations, and how could these developments affect the trading strategy related to SAB Biotherapeutics Inc. Warrant SABSW?
**MWN-AI FAQ is based on asking OpenAI questions about SAB Biotherapeutics Inc. Warrant (NASDAQ: SABSW).
NASDAQ: SABSW
SABSW Trading
-0.24% G/L:
$0.0419 Last:
50,893 Volume:
$0.0312 Open:
